摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-amino-9-((2R,4S,5S)-4-hydroxy-5-(iodomethyl)tetrahydrofuran-2-yl)-1H-purin-6(9H)-one | 140226-19-3

中文名称
——
中文别名
——
英文名称
2-amino-9-((2R,4S,5S)-4-hydroxy-5-(iodomethyl)tetrahydrofuran-2-yl)-1H-purin-6(9H)-one
英文别名
2',5'-dideoxy-5'-iodoguanosine;2-amino-9-[(2R,4S,5S)-4-hydroxy-5-(iodomethyl)oxolan-2-yl]-1H-purin-6-one
2-amino-9-((2R,4S,5S)-4-hydroxy-5-(iodomethyl)tetrahydrofuran-2-yl)-1H-purin-6(9H)-one化学式
CAS
140226-19-3
化学式
C10H12IN5O3
mdl
——
分子量
377.141
InChiKey
SAOBKBRZVFPQAG-KVQBGUIXSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    2.53±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -0.1
  • 重原子数:
    19
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    115
  • 氢给体数:
    3
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-amino-9-((2R,4S,5S)-4-hydroxy-5-(iodomethyl)tetrahydrofuran-2-yl)-1H-purin-6(9H)-one 在 sodium azide 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 生成 2-amino-9-((2R,4S,5R)-5-(azidomethyl)-4-hydroxytetrahydrofuran-2-yl)-1H-purin-6(9H)-one
    参考文献:
    名称:
    [EN] SYNTHETIC PGPG ANALOGS, METHODS OF PREPARATION AND METHODS OF USE
    [FR] ANALOGUES DE PGPG SYNTHÉTIQUES, LEURS PROCÉDÉS DE PRÉPARATION ET LEURS PROCÉDÉS D'UTILISATION
    摘要:
    本发明涉及按照以下式I的化合物及其盐,其中R1、R2、R3、R4和L如本文所定义。还提供了制备式I化合物的方法。本发明还包括使用式I化合物治疗和预防细菌感染的方法,以及识别细菌中pGpG结合结构域的方法。
    公开号:
    WO2013192078A1
  • 作为产物:
    描述:
    2'-脱氧鸟苷吡啶三苯基膦 作用下, 以 1,4-二氧六环 为溶剂, 反应 7.0h, 以45%的产率得到2-amino-9-((2R,4S,5S)-4-hydroxy-5-(iodomethyl)tetrahydrofuran-2-yl)-1H-purin-6(9H)-one
    参考文献:
    名称:
    4'-叠氮基和4'-甲氧基核苷的合成及其抗HIV活性。
    摘要:
    合成了一系列核苷,其中4'-氢被叠氮基或甲氧基取代。合成4'-叠氮基类似物的关键步骤是将叠氮化碘立体和区域选择性加成到4'-不饱和核苷前体中,然后通过氧化辅助置换5'-碘基。4'-甲氧基核苷是通过4'-不饱和核苷的环氧化制得的,合适的环氧化物是用甲醇打开的。反应机理考虑,经验构象规则,基于NMR的构象计算和NOE实验表明4'-叠氮核苷偏爱呋喃糖部分的3'-内(N型)构象。当评估它们在A3.01细胞培养物中对HIV的抑制作用时,所有4'-azido-2' -脱氧-β-D-核苷表现出有效的活性。IC50的范围从4'-叠氮基2'-脱氧尿苷(6c)的0.80 microM到4'-叠氮基2'-脱氧鸟苷(6e)的0.003 microM。在该系列中,检测到的细胞毒性是IC50的50-1500倍。4'-甲氧基-2'-脱氧-β-D-核苷的活性比其叠氮基对应物低2-3个数量级,并且毒性更低。4'-取代的-2
    DOI:
    10.1021/jm00086a013
点击查看最新优质反应信息

文献信息

  • SYNTHETIC pGpG ANALOGS, METHODS OF PREPARATION AND METHODS OF USE
    申请人:TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    公开号:US20150175649A1
    公开(公告)日:2015-06-25
    The present invention relates to compounds according to Formula I: and salts thereof, wherein R 1 , R 2 , R 3 , R 4 , and L are as defined herein. Methods for preparing compounds of Formula I are also provided. The present invention further includes methods of treating and preventing bacterial infections, and methods of identifying pGpG-binding domains in bacteria, using the compounds of Formula I.
    本发明涉及公式I的化合物及其盐,其中R1、R2、R3、R4和L的定义如本文所述。本发明还提供了制备公式I化合物的方法。本发明还包括使用公式I化合物治疗和预防细菌感染的方法,以及识别细菌中pGpG结合域的方法。
  • Antiviral agents
    申请人:SYNTEX (U.S.A.) INC.
    公开号:EP0371366A1
    公开(公告)日:1990-06-06
    Nucleoside compounds of the formula wherein: B is guanine, adenine, thymine, uracil, cytosine, hypoxanthine, xanthine, 5-methylcytosine, 4-ethoxy-5-methyl-2-oxo-pyrimidine, 4-isopropoxy-5-methyl-2-oxo-pyrimidine, or 5-methyl-2-oxo-pyrimidine; X isHorF; Y is H, OH, OCH3 or F; and Z is where n is zero, one, or three and both R are hydrogen or lower alkyl; or Y and Z together form a cyclic phosphate ester; and the pharmaceutically acceptable esters, ethers and salts thereof, have been found to have potent antiviral activity with a high therapeutic ratio.
    式中的核苷化合物 其中 B 是鸟嘌呤腺嘌呤、胸腺嘧啶、尿嘧啶胞嘧啶次黄嘌呤黄嘌呤、5-甲基胞嘧啶、4-乙氧基-5-甲基-2-氧代嘧啶、4-异丙氧基-5-甲基-2-氧代嘧啶或 5-甲基-2-氧代嘧啶; X 是 H 或 F; Y 是 H、OH、OCH3 或 F;以及 Z 是 其中 n 为 0、1 或 3,两个 R 均为氢或低级烷基;或 Y 和 Z 共同形成环磷酸酯;已发现这些药学上可接受的酯、醚和盐具有很强的抗病毒活性和很高的治疗比例。
  • Detection of nucleic acid targets using chemically reactive oligonucleotide probes
    申请人:Dxterity Diagnostics
    公开号:EP2677039A2
    公开(公告)日:2013-12-25
    The present invention provides compositions, apparatuses and methods for detecting one or more nucleic acid targets present in a sample. Methods of the invention include utilizing two or more oligonucleotide probes that reversibly bind a target nucleic acid in close proximity to each other and possess complementary reactive ligation moieties. When such probes have bound to the target in the proper orientation, they are able to undergo a spontaneous chemical ligation reaction that yields a ligated oligonucleotide product. In accordance with the invention, the presence of the target(s) of interest can be determined by measuring the presence or amount of ligated oligonucleotide product.
    本发明提供了用于检测样品中存在的一种或多种核酸靶标的组合物、装置和方法。本发明的方法包括利用两个或多个寡核苷酸探针,这些探针可逆地与靶核酸紧密结合,并具有互补的反应性连接分子。当这些探针以适当的方向与靶核结合后,就能发生自发的化学连接反应,产生连接的寡核苷酸产物。根据本发明,可以通过测量连接寡核苷酸产物的存在或数量来确定是否存在感兴趣的靶标。
  • Chemical ligation dependent probe amplification (CLPA)
    申请人:DXTerity Diagnostics Incorporated
    公开号:EP2765205A1
    公开(公告)日:2014-08-13
    The present invention provides compositions, apparatuses and methods for detecting one or more nucleic acid targets present in a sample. Methods of the invention include utilizing two or more oligonucleotide probes that reversibly bind a target nucleic acid in close proximity to each other and possess complementary reactive ligation moieties. When such probes have bound to the target in the proper orientation, they are able to undergo a spontaneous chemical ligation reaction that yields a ligated oligonucleotide product. In one aspect, the ligation product is of variable length that correlates with a particular target. Following chemical ligation, the probes may be amplified and detected by capillary electrophoresis or microarray analysis.
    本发明提供了用于检测样品中存在的一种或多种核酸靶标的组合物、装置和方法。本发明的方法包括利用两个或多个寡核苷酸探针,这些探针可逆地与靶核酸紧密结合,并具有互补的反应性连接分子。当这些探针以适当的方向与靶核结合后,它们就能发生自发的化学连接反应,产生连接的寡核苷酸产物。在一个方面,连接产物的长度是可变的,与特定的靶标相关。化学连接后,探针可通过毛细管电泳或芯片分析进行扩增和检测。
  • Methods and compositions for detecting target nucleic acids
    申请人:Terbrueggen Robert
    公开号:US10066257B2
    公开(公告)日:2018-09-04
    The present invention provides compositions, apparatuses and methods for detecting one or more nucleic acid targets present in a sample. Methods of the invention include utilizing two or more ligation probes that reversibly bind a target nucleic acid in close proximity to each other and possess complementary reactive ligation moieties. When such probes have bound to the target in the proper orientation, they are able to undergo a spontaneous chemical ligation reaction that yields a ligation product that is directly detected or that is amplified to produce amplicons that are then detected. The present invention also provides methods to stabilize sample RNA so that degradation does not significantly affect the results of the analysis.
    本发明提供了用于检测样品中存在的一种或多种核酸靶标的组合物、装置和方法。本发明的方法包括利用两个或多个可逆结合靶核酸的连接探针,这些探针相互靠近并具有互补的反应性连接分子。当这些探针以适当的方向与靶核酸结合后,它们就能发生自发的化学连接反应,产生可直接检测的连接产物,或经扩增产生可检测的扩增子。本发明还提供了稳定样本 RNA 的方法,使降解不会对分析结果产生重大影响。
查看更多

同类化合物

鲁西他滨 化合物 T14195 [1,1'-联苯基]-2,3,3',4,4',5'-六醇 [(2R,3R,5S)-3-(氨基甲基)-5-(5-甲基-2,4-二氧代嘧啶-1-基)四氢呋喃-2-基]N-[[(2R,3S,5R)-3-羟基-5-(5-甲基-2,4-二氧代嘧啶-1-基)四氢呋喃-2-基]甲基]氨基甲酸酯 9-(2-S-苯甲基-5-脱氧-2-硫代五呋喃糖基)-9H-嘌呤-6-胺 5-脱氧胸苷 5-脱氧-5-[(碘乙酰基)氨基]-胸腺嘧啶脱氧核苷 5-碘-5-脱氧胸腺嘧啶脱氧核苷 5-氨基-5-脱氧胸腺嘧啶脱氧核苷 5-氨基-2,5-二脱氧腺苷酸 5-叠氮基-5-脱氧胸腺嘧啶脱氧核苷 5-三氟乙酰氨基-5-脱氧胸腺嘧啶脱氧核苷 5'-脱氧-5'氟胸苷 5'-脱氧-5'-氯胸苷-3'-(4-硝基苯基)硫代磷酸酯 5'-脱氧-5'-{[4-(甲硫基)苯胺基羰基]氨基}胸苷 5'-脱氧-5'-{[3-(甲硫基)苯胺基羰基]氨基}胸苷 5'-脱氧-5'-[4-苯基-(1,2,3)三唑-1-基]胸苷 5'-脱氧-5'-[4-(甲硫基)苯甲酰氨基]胸苷 5'-脱氧-5'-[4-(吡啶-3-基)-(1,2,3)三唑-1-基]胸苷 5'-脱氧-5'-[4-(4-氟苯基)-(1,2,3)三唑-1-基]胸苷 5'-脱氧-5'-<(苯氧基羰基)氨基>胸苷 5'-硫代-胸苷3',5'-二乙酸酯 5'-溴乙酰氨基-5'-脱氧胸苷 5'-氨基-5-碘-2',5'-二脱氧尿苷 4-氨基-1-((2R,3R,4R,5R)-4-((叔丁基二甲基硅烷基)氧基)-5-(( 2-氯-N-[[3-羟基-5-(5-甲基-2,4-二氧代嘧啶-1-基)四氢呋喃-2-基]甲基]乙酰胺 2-{[(2Z)-3,7-二甲基辛-2,6-二烯-1-基](亚硝基)氨基}乙醇 2,5-二脱氧腺苷 2',5'-二脱氧尿苷 1-[(2R,4S,5R)-4-羟基-5-(异氰基甲基)四氢呋喃-2-基]嘧啶-2,4-二酮 1-[(2R,4S,5R)-4-羟基-5-(异氰基甲基)四氢呋喃-2-基]-5-甲基嘧啶-2,4-二酮 1-(2,5-二脱氧-2-氟-β-D-呋喃阿拉伯糖基)嘧啶-2,4(1H,3H)-二酮 1-(2,5-二脱氧-2-氟-β-D-呋喃阿拉伯糖基)-5-碘嘧啶-2,4(1H,3H)-二酮 N-{9-[(2R,4S,5R)-5-Azidomethyl-4-(tert-butyl-diphenyl-silanyloxy)-tetrahydro-furan-2-yl]-9H-purin-6-yl}-benzamide (Z)-4-(1-(((2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxo-3-((1-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3-triazol-4-yl)methyl)-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl)-1H-1,2,3-triazol-4-ylamino)-4-oxobutane-1,2-diyl dioleate 5'-[4-((1,2-distearoyl-sn-glycer-1-yl)methyl)-1H-1,2,3-triazol-1-yl]-N-3-propargylthymidine 5'-deoxy-5'-hydrazinothymidine hydrochloride N-<5'-Desoxy-thymidinyl-(5')>-phosphorsaeure-<β,β,β-trichlorethylester>-amid Acetic acid (2S,3S,5R)-2-fluoromethyl-5-(5-methyl-2-oxo-4-thioxo-3,4-dihydro-2H-pyrimidin-1-yl)-tetrahydro-furan-3-yl ester N-<5'-Desoxy-thymidinyl-(5')>-phosphorsaeure--amid N-<5'-Desoxy-thymidinyl-(5')>-phosphorsaeure-bis--amid N4-Benzoyl-5'-chlor-2',5'-dideoxycytidin 5'-(bromoacetamido)-2',5'-dideoxy-5-iodouridine 5'-[3-(3-methoxy-2-methyl-acryloyl)-ureido]-5'-deoxy-thymidine 3'-deoxy-5'- O-methyl-3'-(N-(L-p-methoxyphenylalanyl)amino)adenosine 1-(2-deoxy-2-fluoro-4-C-methyl-β-D-arabinofuranosyl)cytosine hydrochloride 5'-N-Isobutyloxycarbonyl-5'-amino-5'-deoxythymidin 4'-chloromethyl-2'-deoxy-2'-fluoro-3'-O-dodecanoylcytidine 3'-O-methylene-5'-deoxy-5'-thiothymidylyl-(3'->5')-N6-benzoyl-3'-O-tert-butyldimethylsilyl-2',5'-dideoxy-5'-thioadenosine